Silver Sulfadiazine Market – Size, Share, Outlook,
and Opportunity Analysis, 2019 – 2027
Silver sulfadiazine is specifically used for second degree or third-degree burns on the skin,
which acts ant-bacterial drug. The World Health Organization considers silver sulfadiazine as an
Essential Medicines and is used as an antibiotic for skin burns. Silver sulfadiazine helps to
prevent growth of yeast and bacteria and is used to treat urinary tract infections (UTI). When it
is combined with pyrimethamine, the combination is used for the treatment of toxoplasmosis.
Furthermore, a typical anti burn cream 1% of silver sulfadiazine contains, which is crucial to
maintain as excessive quantity would make it toxic. However, some organizations do not
recommend its use, as it has been a subject of research and various speculation. Moreover,
there have been some side effects of silver sulfadiazine such as loss of appetite, dizziness, and
nausea.
Request PDF Brochure Of Research Report:
https://www.coherentmarketinsights.com/insight/request-pdf/2763
Market Outlook
Global silver sulfadiazine market size is expected to increase significantly during to forecast
period (2019-2027). Burn injuries are considered severe healthcare problems and far more
serious than other epidemics such as polio. According to the World Health Organization, around
180,000 deaths occur due to burns, majorly in emerging economies. Furthermore, non-fatal
burn injuries are the leading cause of morbidity. This is expected to increase the demand for
anti-burn creams and lotions and subsequently drive the market growth. Furthermore, silver
sulfadiazine has been majorly used hospitals in North America as it is considered as a powerful
treatment for burns.
However, silver sulfadiazine causes minor side effects such as nausea, loss of appetite, and
dizziness, which may hinder the demand for the product and subsequently restrain the global
silver sulfadiazine market growth. Furthermore, increasing the price of silver, which is one of
the prime raw materials for the production of silver sulfadiazine expected to hinder